Endologix says it is on course to file a premarket approval (PMA) application to the US FDA by the end of this year for its PowerLink stent graft for treatment abdominal aortic aneurysms (AAA).
Its announcement came after the release of positive early data from a pivotal trial of the product and news that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?